Moneyta · stock research · no sign-up needed
BMRN
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue
-
Net income
-
as filed with the SEC
Institutions holding
568
+6 last quarter
Overview · BIOMARIN PHARMACEUTICAL INC
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a pro…
Management team
- Ms. Amy Wireman · Executive VP & Chief People OfficerFind on LinkedIn
- Ms. Humaira Serajuddin · Senior VP & Chief Marketing OfficerFind on LinkedIn
- Mr. Alexander Hardy · President, CEO & DirectorFind on LinkedIn
- Mr. Jeffrey Robert Ajer · Executive VP & Chief Commercial OfficerFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on BMRN
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.